Novel antibody–drug conjugates for triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagayama, Aiko, Vidula, Neelima, Ellisen, Leif, Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
TNBC in 2019: Promising Signals for the Special Collection Treatment of a Formidable Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222243/
https://www.ncbi.nlm.nih.gov/pubmed/32426047
http://dx.doi.org/10.1177/1758835920915980
Descripción
Sumario:Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.

Ejemplares similares